Evidence map›Paper›PMID 25106550›Full record

ArticleAnnals of clinical microbiology and antimicrobials2014

Type II and type IV topoisomerase mutations in clinical isolates of Morganella morganii harbouring the qnrD gene.

Mariem Nasri Yaiche, Ikbel Denden Rafraf, Qinglan Guo, Maha Mastouri, Mahjoub Aouni, Minggui Wang

Open access · goldAbstract readCase Reports
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Draft genome sequence of emerging pathogenMicrobiology resource announcements · 2025
    Article
  3. Genomic insights into a Proteus mirabilis strain inducing avian cellulitis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Mariem Nasri YaicheFaculty of Sciences, Bizerta Carthage University, Bizerta, Tunisia. mariem_nasri@hotmail.com.
Ikbel Denden Rafraf
Qinglan Guo
Maha Mastouri
Mahjoub Aouni
Minggui Wang
University of Monastir · TNFudan University · CNHospital Fatuma Bourguiba Monastir · TNHuashan Hospital · CNUniversity of Carthage · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of this study was to show the emergence of the qnrD gene among fluoroquinolone-resistant Morganella morganii isolate. The occurrence of mutations in DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC,parE) genes was also investigated in this strain. METHODOLOGY: 95 clinical Enterobacteria were screened for harbouring the qnrD gene. The clinical isolate of M. morganii was recovered from urine from a patient hospitalized in the urology unit at Fattouma Bourguiba Hospital, Tunisia. Antibiotic susceptibility was tested with the agar disk diffusion method. Quinolone susceptibility was studied with microbroth dilution technique. The investigations of plasmid mediated quinolone resistance (PMQR) and topoisomerases mutations were performed by polymerase chain reaction and nucleotide sequencing.

resultsThis isolate showed high level of resistance to quinolones. The MIC with microbroth dilution technique was 512 μg/ml for norfloxacin, 256 μg/ml for ofloxacin and ciprofloxacin and 64μg/ml for levofloxacin.This strain was found to harbour the quinolone resistance determinant qnrD. In addition, this strain harboured two new gyrB mutations (S463A, S464Y) and one parC mutation (S80I).

conclusionsThis is the first report in Tunisia of qnrD determinant and tow new gyrB muations in M. morganii. The nosocomial infection due to this proteeae invites further study of its epidemiologic evolution.

Indexed as

Drug Resistance, BacterialAgedAnti-Bacterial AgentsDNA, BacterialDNA GyraseDNA Topoisomerase IVDNA Topoisomerases, Type IIEnterobacteriaceae InfectionsFluoroquinolonesHospitalsHumansMaleMicrobial Sensitivity TestsMorganella morganiiMutant ProteinsMutation, MissenseAnti-Bacterial AgentsDNA, BacterialDNA GyraseDNA Topoisomerase IVDNA Topoisomerases, Type IIFluoroquinolonesMutant Proteins

Identifiers

PMID25106550
PMCPMC4236555
OpenAlexW2140513585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.